“About a dozen drugmakers are developing new weight-loss treatments aimed at preserving muscle, and industry analysts, clinical trial experts and doctors say they may also need to demonstrate additional health benefits beyond the numbers on a scale to get approved…

Veru was first with results in January from a 168-person trial, showing its enobosarm helped older patients lose 71% less muscle when taken with Wegovy. Data on Lilly’s muscle mass-preserving drug, bimagrumab, is due this year.”

From Reuters.